Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 in spinal progressive multiple sclerosis
NCT02220933Phase 3Unknown
- Sponsor
- MedDay Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of biotin in multiple sclerosis (MS), sponsored by MedDay Pharmaceuticals. Status: unknown.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02220933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220933.